Skip to main content
Ruanne V Barnabas on Muck Rack

Ruanne V Barnabas

As seen in: Color Research & Application, Nature, Wiley Online Library, PLOS Medicine, BMJ Open, MDPI, JAMA (The Journal of the American Medical Association), The New England Journal of Medicine, EClinicalMedicine, The Lancet and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ruanne V

Contact Ruanne V, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Efficacy and durability of immediate versus delayed single-dose HPV vaccination for persistent infection among young women in Kenya: a randomized, blinded, cross-over clinical trial

|
By Ruanne V Barnabas, Elizabeth Brown, Elizabeth A. Bukusi, Betty Njoroge, Rachel L. Winer, Denise A. Galloway, Charlene Biwott, Syovata Kimanthi, Kate Heller, Susan Morrison Verified, R. Scott McClelland, Nelly R. Mugo, Maricianah Onono, Imeldah N. Wakhungu, Meighan Krows, Elena A. Rechkina, Stephen L. Cherne
| Nature Verified
Abstract Evidence is needed for single-dose human papillomavirus (HPV) vaccine efficacy (VE) durability to support vaccination guidelines. In this randomized crossover trial (NCT03675256), healthy young women aged 15-20 years, recruited through community-based screening in Kenya, were randomly allocated to immediate nonavalent or bivalent HPV vaccination and delayed control at month 30/36 (age 17-23 years), or immediate control and delayed nonavalent HPV vaccination.
Open in Who Shared Issue with article?

Evidence to Action — Single-Dose HPV Vaccination and Cervical HPV Infection | NEJM

|
By Ruanne V Barnabas
| The New England Journal of Medicine Verified
Are you a member of an institution such as a university or hospital?Learn more about Institutional Access Notes This editorial was published on December 3, 2025, at NEJM.org. Disclosure forms provided by the author are available with the full text of this editorial at NEJM.org. Supplementary Material Disclosure Forms (nejme2515387_disclosures.pdf)
Open in Who Shared View Duplicates (4) Issue with article?

Leveraging behavioral economics strategies to close gaps in biomedical HIV prevention

|
By Valerian Mwenda, Grace Umutesi, Ruanne V Barnabas, Jesse Heitner
| PLOS Medicine Verified
Globally, HIV incidence is falling due to tremendous advances in HIV treatment and prevention. However, gaps exist, with 1.3 million new infections globally in 2023 and the world remaining well behind on pre-exposure prophylaxis (PrEP) goals [1]. In 2023, the HIV incidence rate among adolescent girls and young women (AGYW) in southern Africa was over 3 times that of their male counterparts [1], with the gender disparity in Cameroon being a factor of 5 [2].
Open in Who Shared Issue with article?
See all 24 licensed articles (25 Total)